Showing 91 to 100 of 100 results for kidney cancer
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....View recommendations for HTE1
Show all sections
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....View recommendations for HTE2
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive following updated NICE final draft guidance published today (11 January 2024).
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.View recommendations for TA288
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Adults with advanced renal cell carcinoma can now be offered avelumab with axitinib as a first line treatment option on the Cancer Drugs Fund (CDF), NICE has said in final draft guidance.
Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms according to a new quality standard published by NICE today (15 February 2023).
The NHS should offer weight loss surgery to thousands more people in order to tackle an epidemic of type 2 diabetes, says NICE.